



## **Governance Committee Charter**

October 2020

Version 4.0

## Contents

1.	Purpose	3
2.	Role and Responsibilities	3
2.1	Role	3
2.2	Responsibilities	3
3.	Committee Structure and Composition	4
4.	Conflict of Interest	4
5.	Relationship between the Board and the Committee	4
6.	Meeting Procedures	5
6.1	Meetings	5
6.2	Meeting Preparation	5
6.3	Minutes	5
6.4	Attendance at Meetings	5
6.5	Voting	5
6.6	Quorum	5
7.	Performance Evaluation	6
8.	Review of Charter	6
	Endorsement and Approval	6

## 1. Purpose

The Governance Committee (**Committee**) is a committee of the Board of Directors (**Board**) of Illawarra Retirement Trust (**IRT Group**) pursuant to rule 19.10 of its Constitution.

This charter outlines the role and responsibilities of the Committee and governs its meetings and proceedings. Nothing in this charter limits any powers or responsibilities of the Board.

## 2. Role and Responsibilities

### 2.1 Role

The role of the Committee is to advise the Board in relation to corporate, clinical and safety governance items and to oversee performance against these strategies. It is an advisory role and does not relieve any directors of their responsibilities for these matters.

### 2.2 Responsibilities

The Committees Governance responsibilities are:

#### ***Corporate Governance:***

- (a) Review the corporate structure and key board policies, review and endorse the Property Governance Manual and review against appropriate governance standards;
- (b) Review and monitor to determine whether due diligence, compliance, and performance measures and reporting arrangements are adequate;

and provide recommendations to the Board as required.

#### ***Clinical Governance:***

- (a) Oversee clinical risk management, review and endorse Clinical Governance and Quality Improvement frameworks;
- (b) Ensure robust clinical governance arrangements are implemented across IRT and ensure staff and visiting practitioners are empowered to delivery safe and quality clinical care.
- (c) Monitor and evaluate all aspects of clinical care through regular and rigorous review of clinical indicators and trends and customer complaints and feedback;

and provide recommendations to the Board as required.

#### ***Safety Governance:***

- (a) Review and endorse the Work, Health & Safety Framework and key board policies in relation to safety;
- (b) Review and monitor safety incidents reports;

and provide recommendations to the Board as required.

#### ***Financial***

- (a) Review policy and procedures for considering and approving delegations of authority;

and provide recommendations to the Board as required.

### **3. Committee Structure and Composition**

Subject to any variation resolved by the Board, the Committee will comprise a minimum of four (4) independent Directors of IRT including the Chair of the Board (ex-officio). The Committee may second an additional Member from time to time to support its role in relation to clinical governance.

In appointing the members of the Committee, regard will be had to knowledge, skills and experience relevant to:

- (a) governance of corporate, clinical and safety;
- (b) risk and governance.

The Chair of the Committee and each of the members will be appointed annually for a one year term in accordance with the Constitution.

Where a Committee member who is an IRT Director at the time of appointment, ceases for any reason to be an IRT Director or general member, then his or her position as a member of the Committee ceases immediately.

It is acknowledged that a Committee member holds his or her position pursuant to appointment by IRT and must conform to any resolution of the Board.

The Board may, at its discretion, by notice in writing terminate the position of any Committee member and may appoint another in that member's place and a duly signed resolution by an authorised officer of the Company will be evidence thereof.

The number of Committee members may be added to or reduced at any time by resolution of the Board of IRT.

### **4. Conflict of Interest**

All Committee members are required to act in accordance with the Board Charter and to disclose any existing or potential conflicts of interest in relation to matters considered by the Committee.

### **5. Relationship between the Board and the Committee**

Pursuant to the Constitution, the Board may delegate any of its powers in respect of specified matters to Committees by resolution. In the absence of such specific resolution, the Committee will have no power other than to make recommendations to the Board.

A Committee to which powers have been delegated must exercise those powers in accordance with any directions of the Board.

In carrying out its work, the Committee will have access to appropriate resources, including advice of Executive Management and, where necessary, independent advice.

With the approval of the Board, the Committee can co-opt external members from time-to-time to access additional skills, experience and networks.

The Committee has no power to exercise authority over staff, or delegate tasks to any staff, unless the Board and the Group CEO have specifically agreed to such delegations.

## **6. Meeting Procedures**

### **6.1 Meetings**

The provisions of the Constitution for regulating the meetings and proceedings of the Board will also govern the meetings and proceedings of the Committee unless they are not applicable.

The Committee will meet at least four (4) times per year, with regular communications via the Chair of the Committee at other times.

The need for additional meetings will be decided by the Chair of the Committee. Members may make requests to the Chair for additional meetings.

### **6.2 Meeting Preparation**

The Chair of the Committee, working with the Company Secretary or delegate, will set the agenda for each meeting. Members may request the inclusion of specific items on Committee meeting agendas.

The agenda and supporting papers should be distributed to all members in sufficient time before each meeting to enable members to carefully review the papers and be fully prepared for the meeting.

Members are expected to make every reasonable effort to attend meetings of the Committee.

### **6.3 Minutes**

Minutes of meetings of the Committee will be prepared by management, approved by the Chair in draft format, and circulated to all members of the Committee.

Minutes of Committee meetings will be confirmed at the next meeting of the Board and then signed by the Chair as approved.

### **6.4 Attendance at Meetings**

In addition to Committee Members, other Board members may attend Committee meetings but only as non-voting observers.

The Group CEO, Executive General Manager – Finance, Executive General Manager – Quality and Risk, Executive General Manager Aged Care Centres and Executive General Manager – Home Care will attend Committee meetings by standing invitation as non-voting advisers, but may be asked (collectively or individually) by the Chair to absent themselves at any time for all or part of a meeting. Management attendees are not Members of the Committee.

The Committee may invite other persons to meetings as it deems appropriate having regard to management roles and responsibilities that relate to the role and responsibilities of the Committee.

### **6.5 Voting**

In the case of an equality of votes, the Chair of the Committee will have a casting vote in addition to their deliberative vote.

### **6.6 Quorum**

It is necessary to have three (3) members at Committee meetings to form a quorum.

**7. Performance Evaluation**


The Committee will review its performance annually by self-assessment or by appointing an independent professional expert to conduct the evaluation. Evaluation will be conducted as part of the overall Board performance evaluation.

The results of the performance evaluation will be provided to the Board.

**8. Review of Charter**

The Charter will be reviewed annually by the Committee, with any changes to be approved by the Board.

**Endorsement and Approval**



---

Endorsed by the Governance Committee and signed by the Chair



---

Approved by the Board of Directors and signed by the Chair

Date: 22 October 2020